NDA 009435 · Fresenius Kabi USA
Nesacaine-Mpf
Chloroprocaine Hydrochloride · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 2, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1955
Mar 11, 1955
Approved uses
1
Original approval plus efficacy supplements
Registered trials
44
7 Phase 3, 4 recruiting
FAERS reports
34
20 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 29, 2024.
INDICATIONS & USAGE Nesacaine 1% and 2% Injections, in multidose vials with methylparaben as preservative, are indicated for the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia. Nesacaine-MPF 2% and 3% Injections, in single dose vials without preservative and without EDTA, are indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. Nesacaine and Nesacaine-MPF Injections are not to be used for subarachnoid administration.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 11, 1955 Original approval · Type 1 - New Molecular Entity · priority review
6 products under this application
- NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 3% · INJECTABLE, INJECTION · Prescription · TE AP
- NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Discontinued
- NESACAINE · CHLOROPROCAINE HYDROCHLORIDE 1% · INJECTABLE, INJECTION · Discontinued
- NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP
- NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 3% · INJECTABLE, INJECTION · Discontinued
- NESACAINE · CHLOROPROCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Chloroprocaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Local Anesthetic Clinical TrialPivotal-lookingEnrolling by invitation
Baylor Research InstituteAcademic, hospital or other
NCT07601750 · 400 participants (planned) · Start Jan 7, 2025 · Primary completion Dec 2028
Drug: Lidocaine; Bupivacaine Hydrochloride and 2 more · For: Mohs Micrographic Surgery; Anesthesia, Local
Sites: Dallas, Texas
- Multicenter Study of Chloroprocaine Versus Ropivacaine for Epidural Labor AnalgesiaPivotal-lookingStatus unknown
Women's Hospital School Of Medicine Zhejiang UniversityAcademic, hospital or other
NCT06472232 · 356 participants (planned) · Start Jun 18, 2024 · Primary completion Jun 16, 2025
Drug: Chloroprocaine · For: Obstetric Labor
- Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.Pivotal-lookingCompleted
Sintetica SAIndustry
NCT04685538 · 338 participants · Start Sep 9, 2020 · Primary completion Mar 1, 2021
Drug: Chloroprocaine 3%; Tetracaine 0.5% · For: Cataract
Sites: Bologna, Italy; Catanzaro, Italy; Florence, Italy · 27 sites in all
- Pain Selective Anesthesia for Labor Mobility (PSALM Study): a Randomized Controlled Trial of Combined Lidocaine - Chlorprocaine for Labor Epidural AnalgesiaPivotal-lookingRecruiting
Hadassah Medical OrganizationAcademic, hospital or other
NCT06302257 · 303 participants (planned) · Start Mar 12, 2024 · Primary completion Mar 1, 2028
Drug: Chlorprocaine; Lidocaine and 1 more · For: Labor Pain
Sites: Jerusalem, Israel; Rehovot, Israel · 3 sites in all
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPivotal-lookingEnrolling by invitation
Harrow IncIndustry
NCT07456826 · 236 participants (planned) · Start Mar 31, 2026 · Primary completion Aug 2026
Drug: Chloroprocaine Ophthalmic Gel 3% (IHEEZO); Proparacaine Hydrochloride Ophthalmic Solution 0.5% and 1 more · For: Diabetic Macular Edema (DME); Age-Related Macular Degeneration (AMD); Retinal Vein Occlusion and 1 more
Sites: Tyler, Texas
- Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve BlockPivotal-lookingCompleted
Sintetica SAIndustry
NCT02385097 · 211 participants · Start Apr 2015 · Primary completion May 2017
Drug: Chloroprocaine HCl 2%; Ropivacaine 0.75% · For: Axillary Nerve Block
Sites: Gravesano, Switzerland
- Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee ArthroplastyPivotal-lookingNot yet recruiting
Nova Scotia Health AuthorityAcademic, hospital or other
NCT07239999 · 170 participants (planned) · Start Mar 31, 2026 · Primary completion Apr 4, 2027
Drug: Mepivacaine Injection; Chloroprocaine Injection · For: Recovery Period; Anesthesia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective7
- hypotension3
- product label confusion3
- anaesthetic complication2
- areflexia2
- arthralgia2
- back pain2
- bradycardia2
- drug dose omission2
- dyspnoea2
- headache2
- hypoaesthesia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Optimal local anesthetic for spinal anesthesia in patients undergoing ambulatory non-arthroplasty surgery: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
Singh NP, Siddiqui NT, Makkar JK, et al. · Can J Anaesth 2025 · Network Meta-Analysis, Systematic Review
- Local anaesthesia for pain control in first trimester surgical abortion.
Renner RM, Ennis M, McKercher AE, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
- Transient neurologic symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics.
Zaric D, Pace NL · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
- Local anaesthetic nerve block for pain management in labour.
Novikova N, Cluver C · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- 0.75% ropivacaine may be a suitable drug in pregnant women undergoing urgent cesarean delivery during labor analgesia period.
Men X, Wang Q, Dong JF, et al. · BMC Anesthesiol 2024 · Randomized Controlled Trial, Comparative Study
- The effect of pH adjustment of 0.5% bupivacaine on the latency of epidural anesthesia.
Stevens RA, Chester WL, Grueter JA, et al. · Reg Anesth 1989 · Clinical Trial, Comparative Study
Sponsor: Fresenius Kabi USA · Also marketed as Nesacaine
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.